

It is estimated that 43% of women (30 million in the US) suffer from female sexual dysfunction. It is also estimated that 30 million men suffer from ED (erectile dysfunction), with the incidence increasing 2-3-fold between the ages of 40-70. Low sexual desire tends to lead to relationship distress and anxiety.

EC3Health's partner pharmacy is your smart compounding choice... Be smart and call us today 877-536-4635 Ext 701

PT-141, Bremelanotide, is unlike FDA approved PDE5 inhibitors that improve sexual function by improving nitric oxide and vascular function.

PT-141 works on the CNS (Central Nervous System), thus eliciting a more desirous sexual response.

PT-141 is a synthetic, central melanocortin receptor agonist that increases  $\alpha$ -melanocyte stimulating hormone ( $\alpha$ -MSH) in the body. It has been reported to aid in sexual experiences for men and women.

The most common method of treating male sexual dysfunction include PDE5 inhibitors (phosphodiesterase type 5), including Viagra (sildenafil) tadalafil (Cialis®), vardenafil (Levitra®, Staxyn®), and avanafil (Stendra®).

Sildenafil and vardenafil have similar half-lives of 4 hours. PDE5 inhibitors can produce side effects such as dyspepsia, headaches, flushing and priapism (erection lasting more than 4 hours), and they can be involved with serious drug interactions, especially with nitrates.

The next stage in the evolution of personalized medicine is here be a part of it.

## **Research Links:**

- Female
- Male

<sup>\*</sup>EC3Health makes no claims associated with efficacy of any product or therapy.